Abstract:Interest has been recently rekindled in short chain fatty acids (SCFAs) with the emergence of prebiotics and probiotics aimed at improving colonic and systemic health. Dietary carbohydrates, specifically resistant starches and dietary fiber, are substrates for fermentation that produce SCFAs, primarily acetate, propionate, and butyrate, as end products. The rate and amount of SCFA production depends on the species and amounts of microflora present in the colon, the substrate source and gut transit time. SCFAs are readily absorbed. Butyrate is the major energy source for colonocytes. Propionate is largely taken up by the liver. Acetate enters the peripheral circulation to be metabolized by peripheral tissues. Specific SCFA may reduce the risk of developing gastrointestinal disorders, cancer, and cardiovascular disease. Acetate is the principal SCFA in the colon, and after absorption it has been shown to increase cholesterol synthesis. However, propionate, a gluconeogenerator, has been shown to inhibit cholesterol synthesis. Therefore, substrates that can decrease the acetate: propionate ratio may reduce serum lipids and possibly cardiovascular disease risk. Butyrate has been studied for its role in nourishing the colonic mucosa and in the prevention of cancer of the colon, by promoting cell differentiation, cell-cycle arrest and apoptosis of transformed colonocytes; inhibiting the enzyme histone deacetylase and decreasing the transformation of primary to secondary bile acids as a result of colonic acidification. Therefore, a greater increase in SCFA production and potentially a greater delivery of SCFA, specifically butyrate, to the distal colon may result in a protective effect. Butyrate irrigation (enema) has also been suggested in the treatment of colitis. More human studies are now needed, especially, given the diverse nature of carbohydrate substrates and the SCFA patterns resulting from their fermentation. Short-term and long-term human studies are particularly required on SCFAs in relation to markers of cancer risk. These studies will be key to the success of dietary recommendations to maximize colonic disease prevention.

Colonic bacterial metabolites and human health

Bile Acids and Microbiota: Multifaceted and Versatile Regulators of the Liver–Gut Axis

Microbial metabolites as modulators of host physiology

Colonic Health: Fermentation and Short Chain Fatty Acids

Non-SCFA microbial metabolites associated with fiber fermentation and host health

Gut microbial metabolites in obesity, NAFLD and T2DM

The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention

Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health

Short-chain fatty acids, secondary bile acids and indoles: gut microbial metabolites with effects on enteroendocrine cell function and their potential as therapies for metabolic disease

Microbial Regulation of Host Physiology by Short-chain Fatty Acids

Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease

The Gut Microbial Bile Acid Modulation and its Relevance to Digestive Health and Diseases

Interactive Relationships Between Intestinal Flora and Bile Acids.

Diet-induced metabolic changes of the human gut microbiome: importance of short-chain fatty acids, methylamines and indoles

Bile acid metabolism and signaling, the microbiota, and metabolic disease

Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health

Global chemical effects of the microbiome include new bile-acid conjugations

Gut microbiota and health: connecting actors across the metabolic system

From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites

Metabolite interactions between host and microbiota during health and disease: Which feeds the other?

Gut microbial metabolites and its impact on human health